This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by SHIROOZU, A. Articles by YOSHIZUMI, T. Search for Related Content PubMed PubMed Citation Articles by SHIROOZU, A. Articles by YOSHIZUMI, T.

Treatment of Hyperthyroidism with a Small Single Daily Dose of Methimazole

The Second Department of Internal Medicine, Kyushu University Fukuoka Japan
The National Fukuoka Central Hospital, Kyushu University, Fukuoka Japan

Address all correspondence and requests for reprints to: Dr. Akiyo Shiroozu, Second Department of Internal Medicine, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812, Japan.

The duration of action of methimazole (MMI) was studied in patients with hyperthyroidism due to Graves' disease. Perchlorate discharge tests performed 24 h after MMI administration revealed greater than 10% discharge in 77% of 53 patients who received a single dose of 15 mg MMI and in 74% of 23 patients who received 30 mg. The mean percent discharges were 41.5 ±26.4% (±D) and 35.4±28.0, respectively. Based on these results, hyperthyroidism was treated with asingle daily dose (SDD) of 15 mg in 43 patients and with 30 mg in 32 patients, and the results were comparedwith retrospective analysis of 50 patients who were treated with divided doses of MMI (10 mg, 3 times daily). Within 12 weeks, 93% of the patients treatedwith 15 mg SDD, 91% treated with30 mg SDD, and 86% treated with divided doses were euthyroid. Themean times to achieve euthyroidism in these patients were 5.3 ± 3.6 (±SD), 5.3 ± 3.1, and 5.6 ± 3.0 weeks, respectively. Side-effects occurred in 2 patients treated with 15 mg SDD and in 6 treatedwith 30 mg SDD. We conclude that a single daily dose of 15 mg MMI is not only effective in mostpatients with Graves’ hyperthyroidism, but also less frequently causes adverse effects.

^* Present address: The Kaita Hospital, Kaita, Japan.

Received October 17, 1985.

This article has been cited by other articles:

				H. Nakamura, J. Y. Noh, K. Itoh, S. Fukata, A. Miyauchi, N. Hamada, and Working Group of the Japan Thyroid Association for Comparison of Methimazole and Propylthiouracil in Patients with Hyperthyroidism Caused by Graves' Disease J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2157 - 2162. [Abstract] [Full Text] [PDF]

				F. J Vilchez, I. Torres, A. Garcia-Valero, C. Lopez-Tinoco, A. de los Santos, and M. Aguilar-Diosdado Concomitant Agranulocytosis and Hepatotoxicity After Treatment with Carbimazole Ann. Pharmacother., November 1, 2006; 40(11): 2059 - 2063. [Abstract] [Full Text] [PDF]

				J. Ginsberg Diagnosis and management of Graves' disease Can. Med. Assoc. J., March 4, 2003; 168(5): 575 - 585. [Abstract] [Full Text] [PDF]

				S. A. Rivkees, C. Sklar, and M. Freemark The Management of Graves' Disease in Children, with Special Emphasis on Radioiodine Treatment J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3767 - 3776. [Full Text]

				M. B. Genter, N. J. Deamer, B. L. Blake, D. S. Wesley, and P. E. Levi Olfactory Toxicity of Methimazole: Dose-Response and Structure-Activity Studies and Characterization of Flavin-Containing Monooxygenase Activity in the Long-Evans Rat Olfactory Mucosa Toxicol Pathol, July 1, 1995; 23(4): 477 - 486. [Abstract] [PDF]

				E. Roti, E. Gardini, R. Minelli, M. Salvi, G. Robuschi, and L. E. Braverman Methimazole and Serum Thyroid Hormone Concentrations in Hyperthyroid Patients: Effects of Single and Multiple Daily Doses Ann Intern Med, July 15, 1989; 111(2): 181 - 182. [Abstract] [PDF]